EquityZen Growth Technology Fund LLC - Series 1981
Raised
$171K
Investors
5
Min Invest
$10,981
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1981 is a Delaware pooled investment vehicle filed by EquityZen Advisors LLC and Phil Haslett, raising $171K from 5 investors with an $11K minimum investment under Rule 506(b) and Section 3(c). This is part of EquityZen's platform of 1,889 related entities providing pre-IPO exposure through single-company SPVs.
This pre-IPO vehicle follows the standard 506(b) private placement exemption pattern typical of EquityZen's single-company fund series. The $11K minimum investment positions this at the lower-accessibility tier for pre-IPO funds, which typically range from $10K on democratized platforms to $250K+ for institutional offerings.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
